JP2009523421A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009523421A5 JP2009523421A5 JP2008550418A JP2008550418A JP2009523421A5 JP 2009523421 A5 JP2009523421 A5 JP 2009523421A5 JP 2008550418 A JP2008550418 A JP 2008550418A JP 2008550418 A JP2008550418 A JP 2008550418A JP 2009523421 A5 JP2009523421 A5 JP 2009523421A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- antibody
- dkk1
- isolated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical group 0.000 claims 28
- 239000000427 antigen Substances 0.000 claims 20
- 102000036639 antigens Human genes 0.000 claims 20
- 108091007433 antigens Proteins 0.000 claims 20
- 101000864646 Homo sapiens Dickkopf-related protein 1 Proteins 0.000 claims 19
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 claims 17
- 239000000203 mixture Substances 0.000 claims 17
- 239000012634 fragment Substances 0.000 claims 15
- 101000951340 Homo sapiens Dickkopf-related protein 4 Proteins 0.000 claims 14
- 102100037986 Dickkopf-related protein 4 Human genes 0.000 claims 13
- 239000002773 nucleotide Substances 0.000 claims 11
- 125000003729 nucleotide group Chemical group 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 230000003472 neutralizing effect Effects 0.000 claims 7
- 239000013543 active substance Substances 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 208000003076 Osteolysis Diseases 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 208000029791 lytic metastatic bone lesion Diseases 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- 102100030091 Dickkopf-related protein 2 Human genes 0.000 claims 2
- 102100037985 Dickkopf-related protein 3 Human genes 0.000 claims 2
- 102000003964 Histone deacetylase Human genes 0.000 claims 2
- 108090000353 Histone deacetylase Proteins 0.000 claims 2
- 101000864647 Homo sapiens Dickkopf-related protein 2 Proteins 0.000 claims 2
- 101000951342 Homo sapiens Dickkopf-related protein 3 Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102000004067 Osteocalcin Human genes 0.000 claims 2
- 108090000573 Osteocalcin Proteins 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 102000005758 Adenosylmethionine decarboxylase Human genes 0.000 claims 1
- 108010070753 Adenosylmethionine decarboxylase Proteins 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 229940122815 Aromatase inhibitor Drugs 0.000 claims 1
- 229940122361 Bisphosphonate Drugs 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 101150012469 CYS2 gene Proteins 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 108091035707 Consensus sequence Proteins 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 claims 1
- 229940123736 Decarboxylase inhibitor Drugs 0.000 claims 1
- 101710099518 Dickkopf-related protein 1 Proteins 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 102100024025 Heparanase Human genes 0.000 claims 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 241000282567 Macaca fascicularis Species 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000029725 Metabolic bone disease Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 101710181812 Methionine aminopeptidase Proteins 0.000 claims 1
- 102000029749 Microtubule Human genes 0.000 claims 1
- 108091022875 Microtubule Proteins 0.000 claims 1
- 101100223942 Mus musculus Dkk1 gene Proteins 0.000 claims 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010049088 Osteopenia Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 1
- 102000001708 Protein Isoforms Human genes 0.000 claims 1
- 108010029485 Protein Isoforms Proteins 0.000 claims 1
- 229940123934 Reductase inhibitor Drugs 0.000 claims 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 claims 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 claims 1
- 101100222745 Schizosaccharomyces pombe (strain 972 / ATCC 24843) met17 gene Proteins 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 claims 1
- 229940121856 Somatostatin receptor antagonist Drugs 0.000 claims 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 claims 1
- 108091008605 VEGF receptors Proteins 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 230000008485 antagonism Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000002280 anti-androgenic effect Effects 0.000 claims 1
- 230000001772 anti-angiogenic effect Effects 0.000 claims 1
- 229940127003 anti-diabetic drug Drugs 0.000 claims 1
- 229940046836 anti-estrogen Drugs 0.000 claims 1
- 230000001833 anti-estrogenic effect Effects 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 230000000719 anti-leukaemic effect Effects 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940124605 anti-osteoporosis drug Drugs 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 239000000051 antiandrogen Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 239000002814 antineoplastic antimetabolite Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 239000003886 aromatase inhibitor Substances 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 150000004663 bisphosphonates Chemical class 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000000711 cancerogenic effect Effects 0.000 claims 1
- 231100000315 carcinogenic Toxicity 0.000 claims 1
- 230000024245 cell differentiation Effects 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 239000003954 decarboxylase inhibitor Substances 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 239000000328 estrogen antagonist Substances 0.000 claims 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims 1
- 229960001442 gonadorelin Drugs 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 208000024963 hair loss Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 claims 1
- 108010037536 heparanase Proteins 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- 102000050762 human DKK1 Human genes 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 239000000367 immunologic factor Substances 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 claims 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 claims 1
- 210000002752 melanocyte Anatomy 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 210000004688 microtubule Anatomy 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 238000002428 photodynamic therapy Methods 0.000 claims 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical class [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 239000003207 proteasome inhibitor Substances 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 239000003277 telomerase inhibitor Substances 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 230000009261 transgenic effect Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical group OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims 1
- 229940002005 zometa Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75921606P | 2006-01-13 | 2006-01-13 | |
| US60/759,216 | 2006-01-13 | ||
| PCT/US2007/000777 WO2007084344A2 (en) | 2006-01-13 | 2007-01-12 | Compositions and methods of use for antibodies of dickkopf-1 and/or -4 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012274999A Division JP2013099334A (ja) | 2006-01-13 | 2012-12-17 | Ｄｉｃｋｋｏｐｆ−１および／または−４に対する抗体の組成物および製造法その使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009523421A JP2009523421A (ja) | 2009-06-25 |
| JP2009523421A5 true JP2009523421A5 (enExample) | 2010-02-25 |
| JP5552233B2 JP5552233B2 (ja) | 2014-07-16 |
Family
ID=38288117
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008550418A Expired - Fee Related JP5552233B2 (ja) | 2006-01-13 | 2007-01-12 | Ｄｉｃｋｋｏｐｆ−１および／または−４に対する抗体の組成物および製造法その使用方法 |
| JP2012274999A Pending JP2013099334A (ja) | 2006-01-13 | 2012-12-17 | Ｄｉｃｋｋｏｐｆ−１および／または−４に対する抗体の組成物および製造法その使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012274999A Pending JP2013099334A (ja) | 2006-01-13 | 2012-12-17 | Ｄｉｃｋｋｏｐｆ−１および／または−４に対する抗体の組成物および製造法その使用方法 |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US8673306B2 (enExample) |
| EP (1) | EP1976594B1 (enExample) |
| JP (2) | JP5552233B2 (enExample) |
| KR (1) | KR101413785B1 (enExample) |
| CN (1) | CN101400406B (enExample) |
| AR (1) | AR060017A1 (enExample) |
| AU (1) | AU2007207787B2 (enExample) |
| BR (1) | BRPI0706524A2 (enExample) |
| CA (1) | CA2636579A1 (enExample) |
| CR (1) | CR10128A (enExample) |
| CU (1) | CU23871B1 (enExample) |
| EA (1) | EA015538B1 (enExample) |
| EC (1) | ECSP088618A (enExample) |
| GE (1) | GEP20125476B (enExample) |
| HN (1) | HN2008001104A (enExample) |
| IL (1) | IL192631A (enExample) |
| MA (1) | MA30158B1 (enExample) |
| ME (2) | MEP1308A (enExample) |
| MY (1) | MY153573A (enExample) |
| NO (1) | NO20083477L (enExample) |
| NZ (1) | NZ569555A (enExample) |
| PE (2) | PE20071239A1 (enExample) |
| SG (1) | SG169327A1 (enExample) |
| SM (1) | SMP200800042B (enExample) |
| SV (1) | SV2008002980A (enExample) |
| TN (1) | TNSN08297A1 (enExample) |
| TW (1) | TWI432450B (enExample) |
| UA (1) | UA101944C2 (enExample) |
| WO (1) | WO2007084344A2 (enExample) |
| ZA (1) | ZA200805743B (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| US8450274B2 (en) | 2006-05-24 | 2013-05-28 | Theragenetex Co., Ltd. | DKK2 protein and use thereof |
| KR20110117601A (ko) * | 2010-04-21 | 2011-10-27 | 주식회사 테라젠이텍스 | 혈관신생과 연관된 화합물을 탐색하는 방법 |
| JP2009065938A (ja) * | 2007-09-14 | 2009-04-02 | Matsumoto Shika Univ | タンパク質、破骨細胞分化阻害剤、炎症性骨破壊治療薬、遺伝子、組み替えベクター、及びタンパク質の製造方法 |
| TWI489993B (zh) | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法 |
| JP5320730B2 (ja) * | 2007-12-26 | 2013-10-23 | Ｊｎｃ株式会社 | 発光基質水溶液およびその製造方法 |
| CN105079805A (zh) | 2008-09-26 | 2015-11-25 | 昂考梅德药品有限公司 | 卷曲蛋白结合药剂及其应用 |
| WO2010100200A2 (en) * | 2009-03-05 | 2010-09-10 | Novartis Ag | Lyophilised antibody formulation |
| AR075989A1 (es) * | 2009-04-10 | 2011-05-11 | Lilly Co Eli | Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria |
| CA2759078A1 (en) * | 2009-05-07 | 2010-11-11 | Novartis Ag | Compositions and methods of use for binding molecules to dickkopf-1 or dickkopf-4 or both |
| SG175881A1 (en) * | 2009-05-12 | 2011-12-29 | Pfizer | Blocking anti-dkk-1 antibodies and their uses |
| WO2010130832A2 (en) * | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions |
| US20120208208A1 (en) * | 2009-10-30 | 2012-08-16 | Ni Yan G | Pcsk9 immunoassay |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| AU2011225716A1 (en) * | 2010-03-11 | 2012-09-27 | Pfizer Inc. | Antibodies with pH dependent antigen binding |
| NZ602700A (en) | 2010-04-01 | 2014-10-31 | Oncomed Pharm Inc | Frizzled-binding agents and uses thereof |
| EP2632951B1 (en) * | 2010-10-27 | 2017-08-02 | Amgen Inc. | Dkk1 antibodies and methods of use |
| CN103608037B (zh) * | 2011-02-01 | 2016-04-13 | 香港大学 | 抗dkk1单克隆抗体用于治疗肝癌的用途 |
| AU2012223358A1 (en) | 2011-03-01 | 2013-09-05 | Amgen Inc. | Sclerostin and DKK-1 bispecific binding agents |
| CN103487581A (zh) * | 2012-06-08 | 2014-01-01 | 上海市肿瘤研究所 | 血清dkk1在制备甲胎蛋白阴性肝细胞癌的诊断试剂中的用途 |
| CN103472226A (zh) * | 2012-06-08 | 2013-12-25 | 上海市肿瘤研究所 | 血清dkk1在制备早期肝细胞癌或小肝细胞癌的诊断试剂中的用途 |
| UY35148A (es) * | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| AU2014212081A1 (en) * | 2013-02-04 | 2015-08-13 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a Wnt pathway inhibitor |
| CN103083686B (zh) * | 2013-02-18 | 2014-09-10 | 上海交通大学医学院附属仁济医院 | Dkk4基因及其编码蛋白在制备药物中的应用 |
| US9708375B2 (en) | 2013-03-15 | 2017-07-18 | Amgen Inc. | Inhibitory polypeptides specific to WNT inhibitors |
| EP3164194B1 (en) * | 2014-07-03 | 2021-11-24 | Yale University | Dickkopf2 (dkk2) inhibition suppresses tumor formation |
| US12428483B2 (en) | 2014-12-22 | 2025-09-30 | Systimmune, Inc. | Bispecific tetravalent antibodies and methods of making and using thereof |
| DE102016206820B4 (de) | 2015-04-22 | 2017-07-27 | BSH Hausgeräte GmbH | Weiterentwicklung eines Induktionswasserkochers, einer Kaffeemaschine und einer Suppenmaschine |
| SG10202101909RA (en) * | 2015-08-07 | 2021-04-29 | Alx Oncology Inc | Constructs having a sirp-alpha domain or variant thereof |
| CN105203773A (zh) * | 2015-09-28 | 2015-12-30 | 成都博奥新景医学科技有限公司 | 一种人Dickkopf-1蛋白（DKK-1）定量检测试剂盒 |
| AU2016344459B2 (en) | 2015-10-28 | 2023-10-05 | Yale University | Humanized anti-DKK2 antibody and uses thereof |
| RU2656160C2 (ru) * | 2016-08-17 | 2018-05-31 | Закрытое Акционерное Общество "Биокад" | Антитело или его антигенсвязывающий фрагмент, способный связываться с рецептором интерлейкина-6 человека |
| IL266199B2 (en) * | 2016-10-26 | 2025-02-01 | Leap Therapeutics Inc | Using beta-catenin as a biomarker for cancer treatment using anti-DKK-1 antibody |
| WO2018208108A1 (ko) * | 2017-05-10 | 2018-11-15 | 주식회사 굳티셀 | 조절 t 세포에 특이적으로 존재하는 dkk1 단백질 및 그 용도 |
| EP3913055A4 (en) * | 2019-01-15 | 2023-09-27 | Bioneer Corporation | DOUBLE STRANDED OLIGONUCLEOTIDE TARGETED AGAINST DKK1 GENE, CONSTRUCT AND COMPOSITION CONTAINING SAME FOR PREVENTING HAIR LOSS OR PROMOTING HAIR GROWTH THEREFOR |
| US12275781B2 (en) | 2019-02-01 | 2025-04-15 | Board Of Regents, The University Of Texas System | Monoclonal antibodies against MHC-bound human dickkopf-1 peptides and uses thereof |
| AU2020282791A1 (en) | 2019-05-31 | 2021-12-09 | ALX Oncology Inc. | Methods of treating cancer with SIRP alpha Fc fusion in combination with an immune checkpoint inhibitor |
| CN112121147B (zh) * | 2019-06-24 | 2023-07-04 | 中国人民解放军海军特色医学中心 | 多肽在治疗或预防骨髓瘤药物中的应用、多肽、核酸、药物及重组表达载体 |
| CN112180094A (zh) * | 2019-07-04 | 2021-01-05 | 上海东慈生物科技有限公司 | Dkk1抑制剂在预防和/或治疗肿瘤恶病质与糖尿病伴随疾病中的应用 |
| CN111632147A (zh) * | 2020-06-07 | 2020-09-08 | 重庆医科大学 | 骨细胞Wnt激活剂在制备骨折加速愈合、防治骨不连及不运动或失重骨丢失药物中的应用 |
| KR102494042B1 (ko) * | 2020-11-20 | 2023-02-07 | 주식회사 하울바이오 | 인간모유두세포의 성장을 촉진하는 항-dkk-1 항체 및 이의 용도 |
| CN112592402B (zh) * | 2020-12-02 | 2022-04-26 | 杭州奕安济世生物药业有限公司 | 抗dkk2抗体、包含该抗dkk2抗体的组合物及其用途 |
| US20250270304A1 (en) * | 2020-12-23 | 2025-08-28 | Phenomic Ai | Anti-activin antibodies and methods of using the same |
| EP4337190A1 (en) | 2021-05-13 | 2024-03-20 | ALX Oncology Inc. | Combination therapies for treating cancer |
| CN117916377A (zh) * | 2021-09-26 | 2024-04-19 | 安沛治疗有限公司 | 针对dkk1的适体及其用途 |
| WO2023143444A1 (zh) * | 2022-01-28 | 2023-08-03 | 上海君实生物医药科技股份有限公司 | 抗dkk1抗体、其药物组合物及用途 |
| WO2024216064A1 (en) * | 2023-04-14 | 2024-10-17 | Twist Bioscience Corporation | Compositions and methods related to dkk1 binders |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5597710A (en) * | 1994-03-10 | 1997-01-28 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-4 |
| US7057017B2 (en) | 1997-04-16 | 2006-06-06 | Millennium Pharmaceuticals, Inc. | Human dickkopf-related protein and nucleic acid molecules and uses therefor |
| ATE505543T1 (de) | 1997-04-16 | 2011-04-15 | Millennium Pharm Inc | Zusammensetzung, umfassend einen antikörper, der selektiv an ein cysteinreiches sekretiertes protein (crsp) bindet |
| DE19747418C1 (de) | 1997-10-27 | 1999-07-15 | Deutsches Krebsforsch | Inhibitor-Protein des wnt-Signalwegs |
| US7446181B2 (en) * | 1998-01-15 | 2008-11-04 | Millennium Pharmaceuticals, Inc. | Antibodies that bind human Dickkopf-1 proteins |
| AU5233599A (en) | 1998-07-31 | 2000-02-21 | Eli Lilly And Company | Ddkh-3 nucleic acids, polypeptides, vectors, host cells, methods and uses thereof |
| US7026448B2 (en) * | 1998-09-01 | 2006-04-11 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6344541B1 (en) | 1998-09-25 | 2002-02-05 | Amgen Inc. | DKR polypeptides |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| MA26040A1 (fr) | 2001-01-05 | 2004-04-01 | Pfizer | Des anticorps pour recepteur i de facteur de croissance insulinique |
| CA2438245A1 (en) * | 2001-02-16 | 2002-08-29 | Genentech, Inc. | Treatment involving dkk-1 or antagonists thereof |
| DE60237969D1 (de) * | 2001-04-24 | 2010-11-25 | Bayer Corp | Menschliche antikörper gegen timp-1 |
| AU2002359357A1 (en) | 2001-11-07 | 2003-07-09 | The Board Of Trustees Of The University Of Arkansas | Diagnosis prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling |
| AR038568A1 (es) | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
| US7459437B2 (en) | 2002-12-05 | 2008-12-02 | University Of Arkansas For Medical Sciences | Molecular determinants of myeloma bone disease and uses thereof |
| US20050084494A1 (en) | 2003-05-21 | 2005-04-21 | Darwin Prockop | Inhibitors of Dkk-1 |
| JP2008515774A (ja) * | 2004-08-03 | 2008-05-15 | ダイアックス コーポレイション | ｈＫ１結合タンパク質 |
| MX2007001221A (es) * | 2004-08-04 | 2007-03-23 | Amgen Inc | Anticuerpos para proteina dickkopf-1 (dkk-1). |
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| CA2601858A1 (en) | 2005-03-25 | 2006-09-28 | Glycart Biotechnology Ag | Antigen binding molecules directed to mcsp and having increased fc receptor binding affinity and effector function |
| WO2007054816A2 (en) | 2005-11-14 | 2007-05-18 | Bioren, Inc. | Antibody ultrahumanization by predicted mature cdr blasting and cohort library generation and screening |
-
2007
- 2007-01-11 AR ARP070100119A patent/AR060017A1/es unknown
- 2007-01-12 NZ NZ569555A patent/NZ569555A/en not_active IP Right Cessation
- 2007-01-12 ME MEP-13/08A patent/MEP1308A/xx unknown
- 2007-01-12 MY MYPI20082536A patent/MY153573A/en unknown
- 2007-01-12 ME MEP-2008-13A patent/ME00010B/me unknown
- 2007-01-12 AU AU2007207787A patent/AU2007207787B2/en not_active Ceased
- 2007-01-12 SG SG201100297-9A patent/SG169327A1/en unknown
- 2007-01-12 US US12/160,875 patent/US8673306B2/en active Active
- 2007-01-12 CN CN200780009135.2A patent/CN101400406B/zh active Active
- 2007-01-12 CA CA002636579A patent/CA2636579A1/en not_active Abandoned
- 2007-01-12 GE GEAP200710809A patent/GEP20125476B/en unknown
- 2007-01-12 PE PE2007000031A patent/PE20071239A1/es not_active Application Discontinuation
- 2007-01-12 EA EA200801679A patent/EA015538B1/ru not_active IP Right Cessation
- 2007-01-12 UA UAA200808758A patent/UA101944C2/ru unknown
- 2007-01-12 EP EP20070709712 patent/EP1976594B1/en active Active
- 2007-01-12 KR KR1020087019725A patent/KR101413785B1/ko not_active Expired - Fee Related
- 2007-01-12 SM SM200800042T patent/SMP200800042B/it unknown
- 2007-01-12 BR BRPI0706524-8A patent/BRPI0706524A2/pt not_active IP Right Cessation
- 2007-01-12 WO PCT/US2007/000777 patent/WO2007084344A2/en not_active Ceased
- 2007-01-12 TW TW096101263A patent/TWI432450B/zh not_active IP Right Cessation
- 2007-01-12 PE PE2011001865A patent/PE20120816A1/es not_active Application Discontinuation
- 2007-01-12 JP JP2008550418A patent/JP5552233B2/ja not_active Expired - Fee Related
-
2008
- 2008-07-01 ZA ZA200805743A patent/ZA200805743B/xx unknown
- 2008-07-03 IL IL192631A patent/IL192631A/en not_active IP Right Cessation
- 2008-07-04 CU CU20080133A patent/CU23871B1/es not_active IP Right Cessation
- 2008-07-04 CR CR10128A patent/CR10128A/es unknown
- 2008-07-11 MA MA31110A patent/MA30158B1/fr unknown
- 2008-07-11 TN TNP2008000297A patent/TNSN08297A1/en unknown
- 2008-07-11 EC EC2008008618A patent/ECSP088618A/es unknown
- 2008-07-11 SV SV2008002980A patent/SV2008002980A/es unknown
- 2008-07-14 HN HN2008001104A patent/HN2008001104A/es unknown
- 2008-08-11 NO NO20083477A patent/NO20083477L/no not_active Application Discontinuation
-
2012
- 2012-12-17 JP JP2012274999A patent/JP2013099334A/ja active Pending
-
2014
- 2014-01-24 US US14/163,230 patent/US20140341901A1/en not_active Abandoned
- 2014-02-12 US US14/178,892 patent/US9296813B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009523421A5 (enExample) | ||
| AU2010286518B2 (en) | Therapeutic DLL4 binding proteins | |
| JP7621939B2 (ja) | ＲＧＭｃ選択的阻害剤およびその使用 | |
| US9493562B2 (en) | Anti-Siglec-15 antibodies | |
| JP6760840B2 (ja) | アテローム性動脈硬化の処置のためのセマフォリン−４ｄ結合分子の使用 | |
| US20180155429A1 (en) | Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody | |
| US20140212423A1 (en) | Blood-brain barrier penetrating dual specific binding proteins | |
| JP2014503202A (ja) | ＴＮＦ−α結合性タンパク質 | |
| JP2011506483A5 (enExample) | ||
| JP6770312B2 (ja) | 骨疾患の治療 | |
| EP2739311B1 (en) | Method for treating bone gap defects | |
| JP6231632B2 (ja) | Ａｎｇ２抗体 | |
| US12460006B2 (en) | Antibodies against integrin alpha 11 beta 1 | |
| US20240317865A1 (en) | Antibodies against integrin alpha 11 beta 1 | |
| JP2025523477A (ja) | インテグリンアルファ１１ベータ１に対する抗体及びその使用 | |
| TW202504922A (zh) | 用於治療癌症之涉及ｇｒｅｍ１拮抗劑之組合療法 | |
| HK1196251B (en) | Method for treating bone gap defects | |
| HK1196251A (en) | Method for treating bone gap defects |